SCHEMBL26174909

SCHEMBL26174909

CN1CCC(NC(=O)c2cnc3[nH]cc(-c4cc5ccncc5s4)c3c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 1/20 0.41
▸ PDPK1 O15530 2/20 0.41
▸ NTRK1 P04629 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40
▸ CHRNA7 P36544 1/20 0.40
▸ EGLN1 Q9GZT9 3/20 0.40
▸ WNT1 P04628 3/20 0.39
▸ DYRK1A Q13627 3/20 0.39
▸ CDC7 O00311 1/20 0.39
▸ DBF4 Q9UBU7 1/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ IGF1R P08069 2/20 0.39
▸ DYRK1B Q9Y463 1/20 0.39
▸ CCNT1 O60563 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ RET P07949 1/20 0.38
▸ ROCK2 O75116 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26174957 0.84 MAP3K11 (0.49) NTRK1DYRK1AIGF1R
SCHEMBL26175116 0.84 MAPK7 (0.45) NTRK1FLT3NTRK3NTRK2WNT1
SCHEMBL26174995 0.82 DYRK1A (0.35) PDPK1NTRK1CHRNA7DYRK1ACDK2
SCHEMBL26177028 0.81 ABL1 (0.43) NTRK1FLT3NTRK3NTRK2CHRNA7
SCHEMBL26175197 0.81 DYRK1A (0.48) WNT1DYRK1ADYRK1B
SCHEMBL30400148 0.81 DYRK1A (0.48) WNT1DYRK1ADYRK1B
SCHEMBL26176299 0.80 NTRK1 (0.37) NTRK1CHRNA7DYRK1ACDK2CCNT1
SCHEMBL26174832 0.77 CLK1 (0.47) FLT3DYRK1ACDK2IGF1RDYRK1B
SCHEMBL26174949 0.76 DYRK1B (0.50) PDPK1FLT3EGLN1WNT1DYRK1A
SCHEMBL30398793 0.76 ABL1 (0.44) NTRK1FLT3NTRK3NTRK2WNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415817-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
WO-2023064349-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 — — US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 HPGDS 1704/4885PDPK1 8/4885NTRK1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback